NOTRELOAD AI
  • NOTRELOAD AI
  • Invest ↗
  • myNOTRELOAD (BETA)
  • XY Feed
  • 24-HOUR Pass →
Sign in Subscribe

Elliott Takes Aim at Bio-Rad: Activist Investor Pushes for Turnaround

Elliott bought into Bio-Rad to boost its weak stock, betting on turnaround and its valuable Sartorius stake driving future growth.

Elliott Takes Aim at Bio-Rad: Activist Investor Pushes for Turnaround
Credit: Bio-Rad Laboratories
Already have an account? Sign in.
Featured/ 05/18/2026 · 4:53 AM
BIO
/ Don’t stop at just one post.

Related↓

Bio-Rad Faces Headwinds as Citi Downgrades Shares to Neutral
04/07/2026 · 7:45 AM

Bio-Rad Faces Headwinds as Citi Downgrades Shares to Neutral

Citi downgrades Bio-Rad to Neutral, citing weak chromatography growth and China market risks; price target cut to $300.

/ Subscriber only
/ Read more

Feed↓

Adaptive Biotechnologies Plans to Split Its MRD and Immune Medicine Units
06/15/2026 · 4:45 PM

Adaptive Biotechnologies Plans to Split Its MRD and Immune Medicine Units

The company expects to decide the best path by year-end 2026.

/ Subscriber only
Stride Plunges After Losing Major Texas Virtual School Contract
06/15/2026 · 2:52 PM

Stride Plunges After Losing Major Texas Virtual School Contract

Stride shares plunged after Texas' Roscoe ISD decided not to renew its contract for Lone Star Online Academy, representing ~5% of 2025 enrollment. BMO highlights retention risks.

/ Subscriber only
H.C. Wainwright Says CNTX Stock Drop Is 'Overdone' After CTIM-76 Ovarian Cancer Data
06/15/2026 · 1:23 PM

H.C. Wainwright Says CNTX Stock Drop Is 'Overdone' After CTIM-76 Ovarian Cancer Data

Context Therapeutics reported positive Phase 1 data for CTIM-76 in heavily pretreated platinum-resistant ovarian cancer, showing a 29% response rate and good safety, but the stock fell due to small trial size.

/ Subscriber only
  • UP↑
  • Terms/Privacy
  • Sign up
  • Sign in
  • Discord
  • X
  • Bluesky
  • Telegram
  • Reach out →
  • Invest ↗
  • NOTRELOAD AI
DON'T FALL BEHIND. ©2026
Email address Subscribe